Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Staffurth

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Nature Cancer|May 15, 2026
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort studyAnuradha Jayaram, Memuna Rashid, Alison H M Reid, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
BJU International|April 27, 2018
National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meetingMrishta Brizmohun Appayya, Jim Adshead, Hashim U Ahmed, et al.
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
European Urology|October 11, 2016
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT TrialThomas J Johnston, Greg L Shaw, Alastair D Lamb, et al.
BJU International|April 4, 2022
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)Janet Athene Lane, Jenny L Donovan, Grace J Young, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
Nature Cancer|May 15, 2026
Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort studyAnuradha Jayaram, Memuna Rashid, Alison H M Reid, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
BJU International|April 27, 2018
National implementation of multi-parametric magnetic resonance imaging for prostate cancer detection - recommendations from a UK consensus meetingMrishta Brizmohun Appayya, Jim Adshead, Hashim U Ahmed, et al.
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
European Urology|October 11, 2016
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT TrialThomas J Johnston, Greg L Shaw, Alastair D Lamb, et al.
BJU International|April 4, 2022
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)Janet Athene Lane, Jenny L Donovan, Grace J Young, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
Pageof 9